SEARCH

SEARCH BY CITATION

References

  • 1
    Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003;111:450463.
  • 2
    Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 2000;164:19251933.
  • 3
    Kon OM, Sihra BS, Loh LC, Barkans J, Compton CH, Barnes NC et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J 2001;18:4552.
  • 4
    Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006;354:754758.
  • 5
    Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W et al. Tumor necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:10121018.
  • 6
    Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354:697708.
  • 7
    Van der Vaart H, Koeter GH, Postma DS, Kauffman HF, Ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465469.
  • 8
    Cianci R, Cammarota G, Raducci F, Pandolfi F. The impact of biological agents interfering with receptor/ligand binding in the immune system. Eur Rev Med Pharmacol Sci 2005;9:305314.
  • 9
    Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res 2001;2:6670.
  • 10
    Leckie MJ, Ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:21442148.
  • 11
    Kips JC, O’Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:16551659 Epub 2003 Mar 20.
  • 12
    Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:23342339
  • 13
    Braun-Falco M, Fischer S, Plotz SG, Ring J. Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol 2004;151:11031104.
  • 14
    Bryan SA, O’Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:21492153.
  • 15
    Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 2001;179:515.
  • 16
    Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. International natalizumab multiple sclerosis trial group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:1523.
  • 17
    Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P et al. Natalizumab for active Crohn’s disease. N Engl J Med 2003;348:2432.
  • 18
    Podolsky DK. Selective adhesion-molecule therapy and inflammatory bowel disease – a tale of Janus? N Engl J Med 2005;353:19651968.
  • 19
    Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353:362368.
  • 20
    Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369374.
  • 21
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375381.
  • 22
    Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924933.
  • 23
    Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254261.
  • 24
    Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309316.
  • 25
    Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:13781386.
  • 26
    Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:10881094.
  • 27
    Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescent with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265269.
  • 28
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709717.
  • 29
    Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;CD003559.
  • 30
    Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593596
  • 31
    Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH et al. Avon longitudinal study of parents and children study team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348:986993
  • 32
    Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004;113:360361.
  • 33
    Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274280.
  • 34
    Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134140.
  • 35
    Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:6872.
  • 36
    Schwartz RS. Paul Ehrlich’s magic bullets. N Engl J Med 2004;350:10791080.